ArticleJournal of applied clinical medical physics2025
A feasibility study of sexual organ-dose sparing volumetric modulated arc therapy in female low rectal cancer patients treated with three-dimensional conformal radiation therapy.
Article in Journal of applied clinical medical physics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A feasibility study of sexual organ-dose sparing volumetric modulated arc therapy in female low rectal cancer patients treated with three-dimensional conformal radiation therapy.Journal of applied clinical medical physics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundSexual dysfunction is a significant toxicity of pelvic radiation therapy (RT) for female rectal cancer patients and may be more common with intensity-modulated techniques compared to three-dimensional conformal radiation therapy (3D-CRT). However, limited research has evaluated dose sparing of female sexual organs at risk (OARs), particularly erectile tissues that are critical for sexual function. PURPOSE: This feasibility study aimed to demonstrate the practicality of contouring and sparing female sexual OARs in rectal cancer RT by generating sexual organ-sparing volumetric modulated arc therapy (SO-VMAT) plans from a small 3D-CRT cohort and comparing dose distributions to guide future planning.
methodsNine female patients with low rectal adenocarcinoma treated with concurrent chemoradiation using 3D-CRT were retrospectively analyzed. Sexual OARs (bulboclitoris, external genitalia, and vagina) were contoured and incorporated into replanned SO-VMAT plans. Institutional dose-volume constraints were applied for standard OARs and planning target volumes (PTVs). SO-VMAT and 3D-CRT plans were normalized to equal PTV coverage, and dose-volume metrics were compared using Wilcoxon signed-rank tests.
resultsContouring and sparing of female sexual OARs was feasible in all cases. Compared to 3D-CRT, SO-VMAT reduced radiation doses to sexual OARs. For the bulboclitoris, SO-VMAT lowered V3000cGy and V4000cGy (both p = 0.02). For the external genitalia, SO-VMAT reduced maximum and mean dose (both p = 0.02) as well as V1000cGy (p = 0.004) and V2000cGy (p = 0.01). Vaginal sparing was observed at V4000cGy (p = 0.03). SO-VMAT provided significant bladder sparing, whereas bowel and femoral head doses remained comparable. Target coverage remained equivalent between techniques.
conclusionThis study demonstrates that female sexual OARs can be systematically contoured and effectively spared during rectal cancer RT using SO-VMAT. Compared with 3D-CRT, SO-VMAT achieved meaningful dose reductions while maintaining target coverage. These preliminary findings support multi-institutional studies with patient-reported outcomes to validate clinical relevance and guide integration of female sexual OARs into treatment planning.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.